A Ceruloplasmina Como Enzima Marcadora de Atividade Neoplásica Maligna

Authors

  • L. A. Abreu Centro de Pesquisa Básica, Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil
  • R. R. Abreu Centro de Pesquisa Básica, Instituto Nacional de Câncer (INCA). Rio de Janeiro (RJ), Brasil

DOI:

https://doi.org/10.32635/2176-9745.RBC.1984v30n3.3460

Keywords:

Ceruloplasmin/metabolism, Ceruloplasmin/drug effects, Sarcoma, Experimental/enzymology, Cyclophosphamide/pharmacology

Abstract

Hyperceruloplasminemia was detected in U strain isogenic male rats bearing a syngeneic sarcoma in all phases of neoplasm evolution. Normal levels of ceruloplasmin oxidase activity were only observed after lhe first dose of intraperitoneally administered cyclophosphamide (100 mg/kg). However subsequent weekly therapy with the drug did not prevent the return of high levels of sérum ceruloplasmin in the tumor hosts. Healthy rats treated similarly with cyclophosphamide presented a fall in the enzyme activity after the first dose. The constant hyperceruloplasminemia observed suggests the presence of viable latent sarcoma celles and can serve as a biochemical test to monitorize the malignant process.

Downloads

Download data is not yet available.

References

ABREU, L. Á., Contribuição ao estudo da ceruloplasmina. Tese, 1961.

ABREU, L. A., Determination of serum ceruloplasmin oxidative activity. Rev. Brasil. Biol. 21: 97: 103, 1961.

ABREU, L. A. & ABREU, R. R., Serum ceruloplasmin in mice with Ehrlich ascites carcinoma. Experientis 27: 85, 1971. DOI: https://doi.org/10.1007/BF02137757

CALABRESI, P. & PARKS JR, E. R., Alkylating agents, antimetabolites, hormonas, and other antiproliferative agents in GOOD MAN, L. S. & GILMAM, A., The pharmacological basis of therapeuties, Sth edition, New York, Macmillan, Chapter 62, 1254-1307,

GUBLER, C. J., LAHEY, M. E., ASCHENBRUCKER, H., CART-WRIGHT, G. E. & WINTROBE, M. M., Studies on copper metabolism. I. A. method for the determination of copper in whole blood, cells, and plasma. J. Biol. Chem. 196:209-220, 1952. DOI: https://doi.org/10.1016/S0021-9258(18)55722-7

HUGHES, N. R., Serum transferrin and ceruloplasmin concentrations in patients with carcinoma, melanoma, sarcoma and cancers of haematopoietic tíssues. Aust J. Exp. Biol. Med. Sei. 5037-107, 1972. DOI: https://doi.org/10.1038/icb.1972.8

MARUSIC, M, ALLEGRETTI, N. & CULO, F., The timing of cyclophosphamide therapy in tumor-bearing rats affects the resistance to tumor challenae in survivors. Experientia 34: 1355-1356, 1978. DOI: https://doi.org/10.1007/BF01981468

PATERSON, P. Y, DROBISCH, D. C. % BIDDICK, A. S., Cyclophosphamide inhibition of experimental allergic thyroiditis and thyroid antibody produetion. J. Immunol. 106: 570-572, 1971. DOI: https://doi.org/10.4049/jimmunol.106.2.570

PINEDA, E. P., RAVIN, H. A. & RUTENBURG, A. M., Serum ceruloplasmin: observations in patients qith cancer, obstructive jaudice, and other diseases. Gastroenterology 43: 266-270, 1962. DOI: https://doi.org/10.1016/S0016-5085(19)35005-X

RAVIN, H. A., An improved colorimetric anzymatic assay of ceruloplasmin. J. Lab. Clin. Med. 58: 161-168, 1961.

SULLIVAN, J. F. & HART, K. T., Serum benzidine oxidase. J. Lab. Clin. Med. 55: 260-267, 1960.

THOMAS, E. & CONSTANTINESCU, R., Coeruloplasmin modifications by HNa2PO4 administration to rats bearing Jensen carcinoma. Clin. Chim. Acta 13: 708-710, 1966. DOI: https://doi.org/10.1016/0009-8981(66)90134-3

THOMAS, E., OLINESCU, R. & CONSTANTINESCU, R., Coeruloplasmin modifications by HNa2PO4 administration to 0-Ya ascitogen tumor-bearing rats. Clin. Chim. Acta. 13: 711-712, 1966. DOI: https://doi.org/10.1016/0009-8981(66)90135-5

UNGAR-WARON, H., GLUCK-MAN, A., SPIRA, E., WARON, M. & TRAININ, Z., Ceruloplasmin as a marker of neoplastic activity in rabbits bearings the VX-2 carcinoma. Cancer Res. 38: 1296-1299, 1978.

VOELKEL, E. F., LEVINE, L., ALPER, C. A. & TASHJAN JR., A. H., Acute phase reactantes ceruloplasmin and haptoglobin and their reiationship to plasma prostaglandins in rabbits bearing the VX2 carcinoma. J. Exp. Med. 147: 1078-1088, 1978. DOI: https://doi.org/10.1084/jem.147.4.1078

WORTHINGTON, M., RABSON, A. S. & BARON, S., Mechanism of recovery from systemic vaccinia virus infection. 1. The effects of cyclophosphamide. J. Exp. Med. 136: 277-290, 1972. DOI: https://doi.org/10.1084/jem.136.2.277

Published

2023-08-09

How to Cite

1.
Abreu LA, Abreu RR. A Ceruloplasmina Como Enzima Marcadora de Atividade Neoplásica Maligna. Rev. Bras. Cancerol. [Internet]. 2023 Aug. 9 [cited 2024 Nov. 22];30(3):37-40. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3460

Issue

Section

ORIGINAL ARTICLE

Most read articles by the same author(s)